



Published in final edited form as:

Science. 2014 January 3; 343(6166): 94–98. doi:10.1126/science.1243985.

Pregnenolone Can Protect the Brain from Cannabis Intoxication

Monique Vallée^{1,2}, Sergio Vitiello^{1,2,*}, Luigi Bellocchio^{1,2,*}, Etienne Hébert-Chatelain^{1,2,*}, Stéphanie Monlezun^{3,*}, Elena Martin-Garcia⁴, Fernando Kasanetz^{1,2}, Gemma L. Baillie^{5,7}, Francesca Panin^{1,2}, Adeline Cathala^{1,2}, Valérie Roullot-Lacarrière^{1,2}, Sandy Fabre³, Dow P. Hurst⁶, Diane L. Lynch⁶, Derek M. Shore⁶, Véronique Deroche-Gamonet^{1,2}, Umberto Spampinato^{1,2}, Jean-Michel Revest^{1,2}, Rafael Maldonado⁴, Patricia H. Reggio⁶, Ruth A. Ross^{5,7}, Giovanni Marsicano^{1,2,\$}, and Pier Vincenzo Piazza^{1,2,\$}

¹INSERM, Neurocentre Magendie, Physiopathologie de la plasticité neuronale, U862, F-33000 Bordeaux, France

²Univ. Bordeaux, Neurocentre Magendie, Physiopathologie de la plasticité neuronale, U862, F-33000 Bordeaux, France

³Alienor Farma Parc Scientifique Unitec1, 2 Allée du Doyen Georges Brus, 33600 Pessac – France

⁴Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Parc de Recerca Biomédica de Barcelona (PRBB), Calle Dr. Aiguader 88, Barcelona 08003, Spain

⁵Kosterlitz Centre for Therapeutics, Institute of Medical Sciences, University of Aberdeen, Aberdeen, AB25 2ZD, UK

⁶Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro NC USA

Abstract

Pregnenolone is considered the inactive precursor of all steroid hormones and its potential functional effects have been largely neglected. The administration of the main active principle of *Cannabis sativa* (marijuana) ⁹-tetrahydrocannabinol (THC) substantially increases the synthesis of pregnenolone in the brain via the activation of type-1 cannabinoid (CB₁) receptor. Pregnenolone then, acting as a signaling specific inhibitor of the CB₁ receptor, reduces several effects of THC. This negative feedback mediated by pregnenolone reveals an unknown paracrine/autocrine loop protecting the brain from CB₁ receptor over-activation that could open an unforeseen novel approach for the treatment of cannabis intoxication and addiction.

Steroid hormones are important modulators of brain activity and behavior (1–4). Steroids play crucial roles in regulating physiological activities such as food-intake, wakening,

To whom correspondence should be addressed: pier-vincenzo.piazza@inserm.fr.

⁷Present address : Department of Pharmacology & Toxicology, University of Toronto, Medical Sciences Building, 1 King's College Circle, Toronto, Ontario, Canada. M5S 1A8.

*these authors have equally contributed to this work

\$these authors have equally supervised this work

reproduction and sexual behavior and participate in the regulation of mood and memory. Steroids also facilitate coping with stress and have been implicated in stress-related pathologies (1–4).

Although the most studied steroids are produced in the periphery, some of them, named neurosteroids, are also synthesized directly in the brain (5,6) from the putatively inactive precursor pregnenolone (3 β -Hydroxypregn-5-en-20-one) (5). Active neurosteroids, such as pregnenolone-sulfate (20-Oxo-5-pregnen-3 β -yl sulfate), allopregnanolone (3 α -Hydroxy-5 α -pregnan-20-one) and DHEA (3 β -Hydroxyandrost-5-en-17-one), have been implicated in the regulation of mood, cognitive activities and their decline associated with aging-related impairments (5,7).

We investigated the involvement of neurosteroids in addiction by studying the effects of the major classes of drugs of abuse on their production in the brain.

Concentrations of brain steroids were analyzed using gas chromatography coupled to mass spectrometry (GC-MS) (8,9), which allows measuring in the same sample, pregnenolone, DHEA, testosterone (17 β -Hydroxyandrost-4-en-3-one) and its metabolite DHT (17 β -Hydroxy-5 α -androst-3-one) and the three stereoisomers: pregnanolone (3 α -Hydroxy-5 β -pregnan-20-one), allopregnanolone and epiallopregnanolone (3 β -Hydroxy-5 α -pregnan-20-one). As shown for the ventral striatum (the nucleus accumbens, NAc), in the brain of Wistar rats basal levels were approximately 1ng/g of tissue for pregnenolone and testosterone, around 0,4ng/g for allopregnanolone and DHT, whilst only traces of epiallopregnanolone (<0.2ng/g) were found (Fig. 1A). In C57BL/6N mice, the highest concentrations were found for pregnenolone and epiallopregnanolone, whilst the lowest concentrations were observed for testosterone. DHT was undetectable (Fig. S1A). Both in rats and mice brains DHEA and pregnanolone were undetectable in basal conditions and after drugs administration.

Representative compounds of the major classes of drugs of abuse were injected in Wistar rats at doses corresponding approximately to the ED₅₀ for most of their unconditional behavioral effects: cocaine (20mg/kg), morphine (2mg/kg), nicotine (0.4mg/kg), alcohol (1g/kg) and the main active principle of marijuana (*Cannabis sativa*)⁹-tetrahydrocannabinol (THC) (3mg/kg) (10). The increase in pregnenolone (Fig. 1B, Table S1) induced by THC (around 1500%) was several fold higher and longer lasting (2h) than the one induced by the other drugs (around 300% and 30 min). Dose response studies showed a maximal THC-induced increase in pregnenolone of approximately 3000% both in Wistar rats (Fig. 1C) and in C57BL/6N mice (Fig. S1).

The effects of THC on pregnenolone-derived neurosteroids were not statistically significant in mice (Fig. S1). In rats (Fig. 1C) a statistically significant effect was only observed for allopregnanolone (ALLO) and epiallopregnanolone (EPI). However, even at the highest dose of THC (9mg/kg), the increase in these pregnenolone metabolites (Fig. 1C) was several times lower than the increase observed for pregnenolone (in ng/g: ALLO = 0.73 \pm 0.14; EPI = 0.40 \pm 0.08, Preg = 28.38 \pm 3.16).

The highest THC-induced increase in pregnenolone in Wistar rats (Fig. 1D) was observed in the NAc, prefrontal cortex, striatum and thalamus and the lowest in the spinal cord, ventral midbrain, sensory motor cortex and in peripheral tissues such as the kidney, spleen, lung and white fat (Fig. 1E). In the liver, gastrointestinal tract, muscle, testis and plasma, THC had no significant effect.

The effects of THC in the brain are mainly mediated by the type-1 cannabinoid (CB₁) receptor (11–13). In the NAc, similarly to THC, injection to Wistar rats of the CB₁/CB₂ cannabinoid receptor agonists HU210 or WIN55,212-2 increased pregnenolone levels (Fig. 1F) at doses that are in line with their respective affinity for the CB₁ receptor (14). The CB₂-selective agonist JWH133 had no significant effect (Fig. 1F). THC effects on pregnenolone in the NAc were suppressed: 1. by the CB₁ selective antagonist AM251 in Wistar rats (Fig. 1G); 2. in constitutive CB₁ receptor knockout (KO) mice (CB₁^{-/-}, Fig. 1H), which lack CB₁ receptors in all cell types; 3. in conditional mutant mice (17), which lack CB₁ receptors in the majority of striatal GABAergic spiny neurons, i.e. the ones containing the dopamine receptor D₁ (D₁-CB₁^{-/-}) (Fig. 1I) (9). Both CB₁-KO were in mice strains in which the C57BL/6N genotype was predominant (6–7 backcrossing generations). These data indicate that THC increases pregnenolone through activation of the CB₁ receptor.

Pregnenolone is synthesized in the mitochondria from cholesterol by cytochrome P450_{scc} (15, 16). When high levels of steroid synthesis are needed (Fig. 2A), new cholesterol is provided first by hydrolysis of cytoplasmic cholesterol esters by the hormone sensitive lipase (HSL) activated *via* phosphorylation of serine 660. Then, by cholesterol transport into the mitochondria by the steroidogenic acute regulatory protein (StAR) (15,16).

In Wistar rats StAR proteins were not modified by THC (9mg/kg) administration at any time (Fig. 2C,D) (9). In contrast, THC induced a rapid (15 min after THC administration) increase in the levels of P450_{scc} (Fig. 2C,D) that was dependent on the activity of the extracellular signal-regulated kinases 1/2 mitogen-activated protein kinase (Erk1/2^{MAPK}). This rapid increase in P450_{scc} (9) was abolished by the selective inhibitor of Erk1/2^{MAPK} phosphorylation SL327 (100 mg/kg; Fig. 2C,D). Later (30 min after THC administration), an Erk1/2^{MAPK}-independent mechanism sustained the increase in P450_{scc} levels and phosphorylated HSL (Fig. 2C,D). These coordinated modifications can contribute to the increase in pregnenolone induced by THC.

Among the behavioral and somatic CB₁ receptor-dependent effects of THC, the so-called cannabinoid “tetrad” (9, 18) is considered a prototypic signature of cannabinoid intoxication (14). The cannabinoid “tetrad” comprises: hypolocomotion, hypothermia, catalepsy and analgesia. The inhibitor of pregnenolone synthesis, aminoglutethimide (AMG, 50mg/kg) (18) to C57BL/6N mice increased all these behavioral and somatic effects of THC (Fig. 3A–D). The injection of pregnenolone reversed the effects of AMG, inhibited the effects of THC *per se*, but had no effect in animals that did not receive THC (Fig. 3E–H). These data show that THC-induced production of pregnenolone exerts a negative feed-back on CB₁ receptor activity.

Two well-known behavioral disturbances accompany cannabis use in humans: 1. an increase in food palatability and craving that can promote food-intake (19, 20), and 2. a decrease in memory performance (21).

THC increases food intake both in sated rats and in food-deprived C57BL/6N mice (22, 23) and also impairs memory consolidation in an object recognition task in C57BL/6N mice (24). Pregnenolone administration (2–6 mg/kg) blocked THC-induced food-intake in Wistar rats (Fig. 4A) and in C57BL/6N mice (Fig. 4B), and blunted the memory impairment induced by THC in mice (Fig. 4C), but it did not modify these behaviors *per se* (Fig.4A–C). As previously shown (24) THC-induced memory impairments were not due to non-specific motor effects of THC since THC did not modify significantly locomotor activity during the object recognition task.

Cannabinoid drugs modulate brain activity and behavior principally by activation of presynaptic CB₁ receptors, which inhibit the release of several neurotransmitters and in particular GABA and glutamate (25). We assessed the effect of THC on glutamate release (9) by measuring excitatory post-synaptic currents (EPSC) in NAc principal neurons in brain slices obtained from adult Sprague Dawley rats (Fig. 4D,E). Bath application of THC (20 μM) reliably inhibited synaptic transmission in control slices (34.3 ± 3.7 % of inhibition). The effect of THC was significantly attenuated when slices were pre-treated with pregnenolone 100 nM (15.1 ± 1.8 % of inhibition). These effects were likely due to a pre-synaptic action of pregnenolone. Thus, pregnenolone blocked the increase in paired-pulse ratio (PPR) induced by THC (9) but did not modify either the amplitude or the decay time of miniature EPSC (mEPSC) (Table S2). Changes in PPR and in the mEPSC parameters studied here are indicators of changes in neurotransmitter release and in postsynaptic response respectively.

To analyze the potential effects of pregnenolone on the development of cannabis abuse and dependence, we first studied dopamine release in the NAc (9). Activation of dopaminergic neurons and increase in NAc dopamine extracellular levels are common effects of most drugs of abuse and have been implicated in drug addiction (26).

In anaesthetized Sprague Dawley rats, we simultaneously used microdialysis and extracellular unitary recordings (9) to estimate dopamine release in the NAc and the firing activity of dopaminergic neurons in the ventral tegmental area (VTA), respectively. THC, administered intravenously at escalating cumulative doses (0.15, 0.3, 0.6, 1.2 mg/kg) infused at one minute intervals (9), induced a significant increase in extracellular NAc dopamine levels (Fig. 4F) and in the firing activity of VTA neurons (Fig. 4F,G). Both effects were blunted by pre-treatment with pregnenolone (2m/kg) (Fig. 4F,G).

We then analyzed the impact of pregnenolone on the reinforcing effects of cannabinoid drugs using the intravenous self-administration model (9). In this model, CD1 mice were used since this strain readily learns to produce an operant response (i.e. nose-poking into a hole) to obtain an intravenous infusion of CB₁ agonists. Mice readily learned to self-administer the CB₁ agonist WIN55,212-2, showing a clear preference for the device which triggered the infusion of the drug (active hole) in comparison to the inactive device, in

which responding had no scheduled consequences (inactive hole) (Fig. 4H). Injections of pregnenolone (2 and 4mg/kg) before each self-administration session reduced the intake of WIN 55,212-2 (Fig. 4I) and reduced the break-point in a progressive ratio schedule (Fig. 4J), which is considered a reliable measure of the motivation for the drug (9).

To provide first insights on the mechanism of action through which pregnenolone can modify the behavioral and neurobiological effects of THC we studied the effects of pregnenolone in cell lines expressing the human CB₁ (hCB₁) receptor (Fig. S2). Briefly (9), pregnenolone (up to 100 μM) did not modify the equilibrium binding of the radiolabeled CB₁ receptor agonists [3H]CP55,940 and [³H]WIN 55,212-2 (Fig. S2A). In contrast pregnenolone (between 10 nM and 1 μM depending on the cellular model) inhibited the increase in P-Erk1/2^{MAPK} and the decrease in cellular and mitochondrial respiration induced by THC (27) (Fig. S2B-F). This range of pregnenolone concentrations are compatible with the ones (between 10 and 80 ng/g, approximately 30 and 250 nM respectively) that are observed after THC injections (Fig. 1, S1) or pregnenolone injections at behaviorally active doses (Fig. S3). Pregnenolone up to (1 μM) did not decrease the THC-induced reduction of cAMP. These effects suggest that pregnenolone acts as a signaling specific negative allosteric modulator.

Synthetic negative allosteric modulators of CB₁ receptors have been described to display signaling pathway specificity (28,29). However, these drugs increase agonist binding affinity to the CB₁ receptor, increase agonist-induced Erk1/2^{MAPK} phosphorylation and inhibit CB₁ agonist-induced inhibition of adenylyl cyclase (28,29). One possible explanation of these differences is that synthetic antagonists bind to a structural pocket that is devoid of a physiological binding function. In contrast, the endogenous negative allosteric modulator pregnenolone likely binds to a different, evolution-selected, physiologic binding pocket. By using the Forced-Biased Metropolis Monte Carlo simulated annealing program (MMC) (9,30) we found a potential binding pocket for pregnenolone in the lipid facing TMH1/TMH7/Hx8 region of the CB₁ (Fig. S4). This binding pocket was validated using a mutant hCB1 receptor (9) that contained a point mutation that should forbid the binding of the ketone end of pregnenolone to the CB1 (Fig. S5). Pregnenolone lost its inhibitory effects on THC-induced decrease in cellular respiration in cells transfected with the mutant hCB1 receptor (Fig. S5).

The results presented here provide an example of an unforeseen paracrine/autocrine loop, through which brain steroids can control the activity of a GPCR. Thus, CB₁ receptor stimulation increases brain pregnenolone levels, which in turn exerts a negative feedback on the activity of the CB₁ receptor antagonizing most of the known behavioral and somatic effects of THC. Pregnenolone likely acts as a signaling-specific negative allosteric modulator binding to a site distinct from that occupied by orthosteric ligands. Pregnenolone, similarly to some of the other previously described allosteric modulators (31,32), does not modify agonist binding but only agonist efficacy; these effects are compatible with the allosteric two state model (ATSM) (31).

Other drugs of abuse also increased pregnenolone levels, but such an increase was in a much lower range of concentrations than the ones induced by THC, which suggests a different

mechanism of action. However, most drugs of abuse also modify the activity of the endocannabinoid system (33) and could increase pregnenolone through an indirect activation of the CB₁ receptor. This seemed to be the case for cocaine, whose effects on pregnenolone were blocked by pre-treatment with a CB₁ antagonist (Fig. S5).

Although pregnenolone has been considered an inactive precursor, our data indicate that pregnenolone, and not its downstream-derived neurosteroids, inhibits the effects of THC that are mediated by the CB₁ receptors. Thus, in mice, the administration of THC or of pregnenolone, in the range of behaviorally active doses (2–8 mg/kg), did not modify pregnenolone downstream active steroids such as allopregnanolone (Fig. S1, S3). In addition, the administration of allopregnanolone, did not modify behavioral responses to THC, such as THC-induced food-intake (Fig. S6).

An increasing number of synthetic allosteric modulators of GPCRs have been described (28, 29, 31, 32,34,35). However, whether endogenous allosteric modulators physiologically regulate the activity of GPCRs has been questioned (31). Recently, the lipid lipoxin A4 has been proposed as a positive allosteric modulator of CB₁ receptors, suggesting that endogenous modulation of endocannabinoid signaling is a physiological process (36). Our findings confirm and extend this hypothesis uncovering an endogenous negative allosteric modulator of the CB₁ receptor and revealing one of the possible functions of endogenous negative allosterism: the control of a GPCR over-activation.

Allosteric modulators may offer several advantages as therapeutic drugs (31,32,34,35). Allosteric modulators do not modify the activity of the receptors *per se*, but enhance or attenuate the effects of endogenous or exogenous ligands. Allosteric drugs can also be signaling-specific, thereby regulating only some of the functions of the receptor. As such, they respect the physiology of the target system, can modify only the signaling pathway involved in the disease, and have a more targeted action than orthosteric compounds (31,32,34,35).

In comparison with orthosteric antagonist, drugs with the pharmacological profile of pregnenolone could have supplementary advantages for the treatment of drug dependence. When used at high doses, which effectively block the activity of the target receptor, orthosteric antagonists often induce a profound discomfort that is not well tolerated by patients. Lower doses of orthosteric antagonists are also not practical because their reversible antagonism can be overcome by taking higher doses of the drug. Signaling-pathway specific allosteric inhibitors, such as pregnenolone, should be better tolerated because: 1. they do not produce an inhibition of all CB₁ receptor activities and 2. their insurmountable effects cannot be overcome by increasing drug intake.

In conclusion, this new understanding of the role of pregnenolone has the potential to generate new therapies for cannabis dependence.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We are grateful to Agnès Grel, Anne Le Roux, and Cédric Dupuy for technical help. Supported by INSERM, the University Victor Segalen-Bordeaux2, Structure Fédérative de Recherche Neurosciences (SFRn) de l'Université de Bordeaux and Region Aquitaine funds (M.V., S.V., L.B., F.P., A.C., V.D-G., J-M.R., U.S., G.M. and P.V.P.) and INSERM (G.M.), EU-FP7 (REPROBESITY, HEALTH-F2-2008-223713, G.M.), European Research Council (ENDOFOOD, ERC-2010-StG-260515, G.M.), Fondation pour la Recherche Médicale (G.M.), the Agence Nationale pour la Recherche (ANR; contracts HICOMET and TIMMS, P.V.P.), NIH (DA-03672, DA-003934, DA-09789, R.A.R. and G.L.B.) NIH (RO1 DA003934 and KO5 DA021358 PHR) grants. Patent pending.

References and Notes

1. Piazza PV, Le Moal M. *Brain Res Brain Res Rev.* 1997; 25:359–372. [PubMed: 9495563]
2. De Kloet ER, Joels M, Holsboer F. *Nat Rev Neurosci.* 2005; 6:463–475. [PubMed: 15891777]
3. McEwen BS, Gianaros PJ. *Annu Rev Med.* 2011; 62:431–445. [PubMed: 20707675]
4. Sandi C. *Nat Rev Neurosci.* 2004; 5:917–930. [PubMed: 15550947]
5. Baulieu EE, et al. *Int Rev Neurobiol.* 2001; 46:1–32. [PubMed: 11599297]
6. Porcu P, et al. *Steroids.* 2009; 74:463–473. [PubMed: 19171160]
7. Vallée M, et al. *Int Rev Neurobiol.* 2001; 46:273–320. [PubMed: 11599303]
8. Krone N, et al. *J Steroid Biochem Mol Biol.* 2010; 121:496–504. [PubMed: 20417277]
9. Materials and methods and supporting data are available on *Science Online*.
10. Gaoni Y, Mechoulam R. *J Am Chem Soc.* 1964; 86:1646–1647.
11. Marsicano G, Lutz B. *J Endocrinol Invest.* 2006; 29:27–46. [PubMed: 16751707]
12. Piomelli D. *Nat Rev Neurosci.* 2003; 4:873–884. [PubMed: 14595399]
13. Mackie K, Stella N. *AAPSJ.* 2006; 8:E298–E306. [PubMed: 16796380]
14. Howlett AC, et al. *Pharmacol Rev.* 2002; 54:161–202. [PubMed: 12037135]
15. Manna PR, et al. *J Biol Chem.* 2013; 288:8505–8518. [PubMed: 23362264]
16. Stocco DM, Wang X, Jo Y, Manna PR. *Mol Endocrinol.* 2005; 19:2647–2659. [PubMed: 15831519]
17. Monory K, et al. *PLoS Biol.* 2007; 5:e269. [PubMed: 17927447]
18. Foster AB, et al. *J Med Chem.* 1983; 26:50–54. [PubMed: 6827528]
19. Greenberg I, et al. *Psychopharmacology (Berl).* 1976; 49:79–84. [PubMed: 822452]
20. Kirkham TC. *Behav Pharmacol.* 2005; 16:297–313. [PubMed: 16148436]
21. Lundqvist T. *Pharmacol Biochem Behav.* 2005; 81:319–330. [PubMed: 15925403]
22. Bellocchio L, et al. *Nat Neurosci.* 2010; 13:281–283. [PubMed: 20139974]
23. Williams CM, et al. *Physiol Behav.* 1998; 65:343–346. [PubMed: 9855485]
24. Puighermanal E, et al. *Neuropsychopharmacology.* 2013; 38:1334–43.
25. Kano M, Ohno-Shosaku T, Hashimoto-dani Y, Uchigashima M, Watanabe M. *Physiol Rev.* 2009; 89:309–380. [PubMed: 19126760]
26. Di Chiara G, Bassareo V. *Curr Opin Pharmacol.* 2007; 7:69–76. [PubMed: 17174602]
27. Bénard G, et al. *Nat Neurosci.* 2012; 15:558–564. [PubMed: 22388959]
28. Ahn KH, Mahmoud MM, Kendall DA. *J Biol Chem.* 2012; 287:12070–12082. [PubMed: 22343625]
29. Baillie GL, et al. *Mol Pharmacol.* 2013; 83:322–338. [PubMed: 23160940]
30. Clark M, Guarnieri F, Shkurko I, Wiseman J. *J Chem Inf Model.* 2006; 46:231–242. [PubMed: 16426059]
31. May LT, Leach L, Sexton PM, Christopoulos A. *Annu Rev Pharmacol Toxicol.* 2007; 47:1–51. [PubMed: 17009927]
32. Kenakin TP. *Br J Pharmacol.* 2012; 165:1659–1669. [PubMed: 22023017]
33. Maldonado R, Valverde O, Berrendero F. *Trends Neurosci.* 2006; 29:225–232. [PubMed: 16483675]
34. Ross RA. *Trends Pharmacol Sci.* 2007; 28:567–572. [PubMed: 18029031]

35. Christopoulos A, Kenakin T. *Pharmacol Rev.* 2002; 54:323–374. [PubMed: 12037145]
36. Pamplona FA, et al. *Proc Natl Acad Sci U S A.* 2012; 109:21134–21139. [PubMed: 23150578]




Fig. 1. THC increases pregnenolone levels by activating the CB₁ receptor. (A) Basal levels of pregnenolone (PREG), allopregnanolone (ALLO), epiallopregnanolone (EPI), testosterone (T) and dihydrotestosterone (DHT) in the NAc. (B) Compared to the major classes of drugs of abuse, cocaine (20 mg/kg, ip), morphine (2 mg/kg, ip), nicotine (0.4 mg/kg, ip) and ethanol (1 g/kg, ip), THC (3 mg/kg, ip) induced the highest increase in pregnenolone concentrations in the NAc. Arrows indicate the time of drug injection. (C) THC dose-dependently increased [F(6,30) = 17.2; $p < 0.001$] pregnenolone concentrations in the NAc with minor effects on pregnenolone-derived downstream steroids. (D,E) THC at 9 mg/kg differently increased pregnenolone concentrations in brain structures and peripheral tissues: prefrontal cortex (FCX), nucleus accumbens (NAc), dorsal striatum (STR), hippocampus (HPC), thalamus (THA), hypothalamus (HYP), ventral midbrain (VMB), sensory motor cortex (CX), cerebellum (CB), spinal cord (SPI), kidney (KID), liver (LIV), spleen (SPL), lung (LUN), intestine (INT), muscle (MUS), white adipose tissue (WAT), testis (TES) and plasma. (F) In the NAc, the intraperitoneal (ip) injection of the CB₁ agonists HU210 and WIN 55,212-2 dose-dependently increased pregnenolone levels [ANOVA $p < 0.001$, in all cases]. The CB₂ agonist JWH-133 had non-statistically significant effects. (G) The increase in pregnenolone concentrations induced by THC (3 mg/kg, ip) in the NAc was abolished by the CB₁ antagonist, AM251 (8mg/kg, ip) injected 30 min before THC. THC (12 mg/kg, ip) induced an increase in pregnenolone levels in the NAc of wild-type mice, but not in knockout mice with a (H) complete ($CB_1^{-/-}$) or (I) neuron specific ($D_1-CB_1^{-/-}$) deletion of the CB₁ receptor. Data are expressed as mean \pm SEM ($n = 6-12$ per group). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ compared to animals that did not receive THC. All experiment except (H) and (I) were performed in Wistar rats.




Fig. 2.

THC can increase pregnenolone synthesis through proteins involved in neurosteroidogenesis. Schematic representation of (A) the proposed molecular mechanism and (B) of the protocol used. (C) Representatives Western blots and (D) densitometric quantification of NAc expression of cytochrome P450scc, StAR, P-HSL^{Ser660}, HSL and β III-tubulin proteins, in Wistar rats intraperitoneally injected with THC (9 mg/kg) after treatment with SL327 or vehicle. 15 min after THC administration the levels of cytochrome P450scc increased via an Erk1/2^{MAPK}-dependent mechanism. 30 min after THC administration, with an Erk1/2^{MAPK}-independent mechanism, cytochrome P450scc was still increased and the hormone sensitive lipase (HSL) was activated by phosphorylation. THC administration did not modify the levels of StAR proteins. Data are expressed as mean \pm SEM (n = 5–7 per group). OD = Optical Density. *p < 0.05, ***p < 0.001 in comparison to vehicle-treated rats (white and white striped bars). #p < 0.05, ##p < 0.005, ###p < 0.001 in comparison to THC-treated rats (black and black striped bars). Fisher's PLSD *post-hoc* test after ANOVA.




Fig. 3. The cannabinoid tetrad induced by THC was inhibited by pregnenolone. In C57Bl/6N mice, the administration, 30 min before THC, of aminoglutethimide (AMG, 50 mg/kg, ip), a P450_{sc} inhibitor that blocks pregnenolone synthesis, increased the effects of THC: (A) hypocomotion [$F(3,98) = 13.8, p < 0.001$], (B) hypothermia [$F(3,98) = 4.7, p < 0.01$], (C) catalepsy [$F(3,98) = 2.1, p < 0.05$], and (D) analgesia [$F(3,98) = 2.2, p < 0.05$]. (E–H) Pregnenolone (PREG, 6 mg/kg, sc) administered at the same time that AMG (50 mg/kg, ip) prevented the increase in the responses to THC (10 mg/kg, ip) induced by AMG. Injection of pregnenolone (PREG 6 mg/kg, sc) alone 30 min before THC (10 mg/kg, ip) also reduced the behavioral effects of THC. Pregnenolone had no effects in animals that did not receive THC. Data are expressed as mean \pm SEM ($n = 6$ –12 per group). * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$ compared to vehicle treated mice.




Fig. 4.

Pregnenolone inhibits behavioral and neurobiological effects of cannabinoids drugs. Pregnenolone injections inhibited the increase in food-intake in (A) *ad-libitum* fed Wistar rats [$F(3,94) = 3.65$; $p < 0.02$] and in (B) 24h-food deprived C57Bl/6N mice, as well as (C) the memory impairment [$F(3,23) = 24.6$, $p < 0.001$] induced by THC in C57Bl/6N mice. (D) Bath application of THC (20 μM) inhibited glutamatergic synaptic transmission in NAC principal neurons in brain slices obtained from adult Sprague Dawley rats (controls $n = 8$). This effect was reduced when brain slices were preincubated with pregnenolone 100 nM ($n = 9$). (E) Synaptic current traces from representative experiments averaged during baseline and after 40 minutes of THC exposure. Pregnenolone injections (2mg/kg, sc 30 min before THC) in Sprague Dawley rats decreased THC-induced increase in (F) the firing rate of ventral tegmental area (VTA) dopaminergic neurons [$F(4,48) = 8.33$, $p < 0.001$] and in (G) the dopamine outflow in the nucleus accumbens (NAc) [$F(10,120) = 20.28$, $p < 0.001$]. THC was administered intravenously at escalating cumulative doses (0.15, 0.3, 0.6, 1.2 mg/kg) infused at one minute intervals. (H) CD1 mice acquired intravenous self-administration of the cannabinoid agonists WIN 55,512-2 (0.0125 mg/kg/infusion) as shown by the higher number of nose-pokes in the active device (hole) than in the inactive one [$F(1,18) = 38.3$, p

< 0.001]. (I) After acquisition, the injection of pregnenolone (PREG, 2 or 4 mg/kg, sc) decreased the number of responses in the active device. (J) Pregnenolone also decreased the motivation for WIN 55,512-2 as measured by the reduction in the break-point in a progressive ratio schedule. Data are expressed as mean \pm SEM. A,B,C (n = 6–12 per group), F,G (n = 6–7 per group), H,I,J (n = 8 per group). Arrow indicates the time of pregnenolone injection, *p < 0.05, **p < 0.01, ***p < 0.001 vs vehicle-treated controls.